After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the biologic ...

Argatroban could revive the practice of acute anticoagulation for reducing disability after stroke, based on the EASE trial from China. In patients with acute ischemic stroke and early neurological ...

(San Diego, Calif., December 7, 2003) – The use of ximelagatran in patients with acute venous thromboembolism is as safe and effective as the current standard treatment of enoxaparin, according to a ...

Potent new anticoagulants have been discovered in the genetic code responsible for the saliva of blood-sucking ticks. Anticoagulants, also known as blood thinners, help prevent unwanted blood clotting ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Direct thrombin inhibitors prevent the conversion of fibrinogen into fibrin during the coagulation cascade and ultimately prevent the development of a thrombus. 11 Dabigatran etexilate was the first ...

Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with ...

Direct oral anticoagulants (DOACs) have transformed venous thromboembolism (VTE) treatment by offering predictable pharmacokinetics and eliminating routine monitoring requirements. Despite robust ...

Coadministration of dabigatran etexilate with the antiplatelet drug clopidogrel had no effect on dabigratran's anticoagulant activity as measured by ECT, activated partial thromboplastin time (aPTT), ...

A growing body of evidence indicates that coagulation factors may exhibit not only prothrombotic but also proatherogenic effects. Recent years have yielded numerous animal studies demonstrating that ...